Literature DB >> 22574231

ACR Appropriateness Criteria®-Recurrent Rectal Cancer.

Andre A Konski, W Warren Suh, Joseph M Herman, A William Blackstock, Theodore S Hong, Matthew M Poggi, Miguel Rodriguez-Bigas, William Small, Charles R Thomas, Jennifer Zook.   

Abstract

The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions. These Criteria are reviewed every 2 years by a multidisciplinary expert panel. The development and review of these guidelines includes an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.Local recurrence of rectal cancer can result in devastating symptoms for patients, including intractable pain and discharge. Prior treatment can limit subsequent treatment options. Preoperative 5-FU based chemoradiotherapy is the treatment of choice for patients with a local recurrence who did not receive adjuvant therapy after initial resection or who might have received chemotherapy alone. Chemoradiotherapy followed by evaluation for surgery is the preferred treatment for patients who have undergone previous radiotherapy after surgery. The inclusion of surgery has resulted in the best outcomes in a majority of studies. Palliative chemoradiotherapy is appropriate for patients who have received previous radiotherapy whose recurrent disease is considered inoperable. Radiotherapy can be delivered on a standard or hyperfractionated treatment schedule.Newer systemic treatments have improved response rates and given physicians more options for treating patients in this difficult situation. The use of induction chemotherapy prior to radiotherapy is an evolving treatment option. Specialized treatment modalities should be used at institutions with experience in these techniques and preferably in patients enrolled in clinical trials.

Entities:  

Keywords:  Appropriateness Criteria; Local recurrent rectal cancer; chemoradiotherapy; re-irradiation

Year:  2012        PMID: 22574231      PMCID: PMC3348710     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN: 1934-7820


  43 in total

1.  Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.

Authors:  Vincenzo Valentini; Alessio G Morganti; M Antonietta Gambacorta; Mohammed Mohiuddin; G Battista Doglietto; Claudio Coco; Antonino De Paoli; Carlo Rossi; Annamaria Di Russo; Francesca Valvo; Giampaolo Bolzicco; Maurizio Dalla Palma
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-18       Impact factor: 7.038

2.  Comparison of intraoperative radiation therapy-containing multimodality treatment with historical treatment modalities for locally recurrent rectal cancer.

Authors:  G H Mannaerts; H J Rutten; H Martijn; P E Hanssens; T Wiggers
Journal:  Dis Colon Rectum       Date:  2001-12       Impact factor: 4.585

3.  Preoperative radiotherapy improves outcome in recurrent rectal cancer.

Authors:  Maarten Vermaas; Floris T J Ferenschild; Joost J M E Nuyttens; Andreas W K S Marinelli; Theo Wiggers; Joost R M M van der Sijp; Cornelis Verhoef; Wilfried J Graveland; Alexander M M Eggermont; Johannes H W de Wilt
Journal:  Dis Colon Rectum       Date:  2005-05       Impact factor: 4.585

Review 4.  Intraoperative radiation therapy.

Authors:  Christopher G Willett; Brian G Czito; Douglas S Tyler
Journal:  J Clin Oncol       Date:  2007-03-10       Impact factor: 44.544

5.  Curative surgical resection following reirradiation for recurrent rectal cancer.

Authors:  M Mohiuddin; G M Marks; V Lingareddy; J Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-10-01       Impact factor: 7.038

6.  Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity.

Authors:  C R Shumate; T A Rich; J M Skibber; J A Ajani; D M Ota
Journal:  Cancer       Date:  1993-06-01       Impact factor: 6.860

7.  Locally recurrent rectal cancer: prognostic factors and long-term outcomes of multimodal therapy.

Authors:  Fabio Pacelli; Antonio P Tortorelli; Fausto Rosa; Maurizio Bossola; Alejandro M Sanchez; Valerio Papa; Vincenzo Valentini; Giovanni B Doglietto
Journal:  Ann Surg Oncol       Date:  2009-10-16       Impact factor: 5.344

8.  A randomized feasibility study evaluating the effect of radiotherapy alone or combined with 5-fluorouracil in the treatment of locally recurrent or inoperable colorectal carcinoma.

Authors:  M Overgaard; K Bertelsen; M Dalmark; C C Gadeberg; H von der Maase; J Overgaard; A Sell
Journal:  Acta Oncol       Date:  1993       Impact factor: 4.089

9.  Surgery and pre-operative irradiation for locally advanced or recurrent rectal cancer in patients over 75 years of age.

Authors:  S G Larsen; J N Wiig; S Tretli; K-E Giercksky
Journal:  Colorectal Dis       Date:  2006-03       Impact factor: 3.788

10.  Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer.

Authors:  K Suzuki; L L Gunderson; R M Devine; A L Weaver; R R Dozois; D M Ilstrup; J A Martenson; M J O'Connell
Journal:  Cancer       Date:  1995-02-15       Impact factor: 6.860

View more
  2 in total

1.  Intraoperative radiotherapy with low energy photons in recurrent colorectal cancer: a single centre retrospective study.

Authors:  Magdalena Skórzewska; Jerzy Mielko; Andrzej Kurylcio; Jarosław Romanek; Wojciech P Polkowski
Journal:  Contemp Oncol (Pozn)       Date:  2016-03-16

2.  Effect of alpha-lipoic acid on radiation-induced small intestine injury in mice.

Authors:  Bae Kwon Jeong; Jin Ho Song; Hojin Jeong; Hoon Sik Choi; Jung Hwa Jung; Jong Ryeal Hahm; Seung Hoon Woo; Myeong Hee Jung; Bong-Hoi Choi; Jin Hyun Kim; Ki Mun Kang
Journal:  Oncotarget       Date:  2016-03-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.